In the LAAO group, 59.7% did not have prior OAC use, whereas 40.3% did. In the LAAO group, 27.0% died, 39.9% experienced bleeding, and 7.2% had nonfatal strokes. Less than one-third of patients with kidney failure and atrial fibrillation are prescribed OACs because uremia confers excess bleeding risk, the investigators pointed out. LAAO may be beneficial because most thrombi from atrial fibrillation occur in the left atrial appendage. Only apixaban 5 mg twice daily was associated with a lower risk of all-cause mortality compared to non-OAC use (HR, .67; 95% CI, .490–.919).